Radiation therapy

Radiotherapy Market to Cross $17,194.4 Million Revenue by 2030 Says P&S Intelligence

Thursday, August 6, 2020 - 1:30pm

Additionally, the American Institute of Cancer Research says that by 2030, around 25 million cases will be diagnosed every year.

Key Points: 
  • Additionally, the American Institute of Cancer Research says that by 2030, around 25 million cases will be diagnosed every year.
  • Due to the coronavirus pandemic, the radiotherapy market is witnessing subdued growth, as the focus of the healthcare fraternity has shifted from chronic diseases to mitigating the COVID-19 spread.
  • The external beam category, on the basis of type, held the largest share in the radiotherapy market in the past.
  • During the next decade, the fastest growth in the radiotherapy market would be witnessed by the hospitals division, under the end-user segment.

TAE Life Sciences to Present at Solebury Trout Summer 2020 Private Company Showcase

Thursday, August 6, 2020 - 12:00pm

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), today announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), today announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.
  • TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).
  • TLSs drug and device are currently in development and have not been approved for sale.
  • More information about TAE Life Sciences is available at www.taelifesciences.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005246/en/

Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments

Wednesday, August 5, 2020 - 1:15pm

The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.

Key Points: 
  • The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.
  • Vyripharms drug platform technology is a personalized medicine application for diagnosis, monitoring and treatment of some infectious diseases, neurological disorders and cancers.
  • Moreover, the platform provides a means for labeling diagnostic and therapeutic agents to allow for tissue specific targeted diagnostic imaging and radiotherapy.
  • We are excited at the prospect of a great collaboration to effectively study these challenging neurological disorders.

Mevion Selected to Provide Proton Therapy System in Córdoba, Spain

Wednesday, August 5, 2020 - 12:00pm

In the initiative, Mevion will provide its revolutionary MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning which will be made available to Andalusian Health Service patients.

Key Points: 
  • In the initiative, Mevion will provide its revolutionary MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning which will be made available to Andalusian Health Service patients.
  • View the full release here: https://www.businesswire.com/news/home/20200805005278/en/
    MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning.
  • To learn more about the proton therapy initiative in Crdoba, Spain, please see the University of Cordoba's announcement .
  • Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients.

Radiation Business Solutions Continues To Grow National Radiation Oncology Network Through Acquisition Of MBR Medical Billing, Inc.

Tuesday, August 4, 2020 - 12:06pm

NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ --Radiation Business Solutions (RBS) announced that they have reached an agreement to purchase MBR Medical Billing, Inc., a radiation oncology medical billing company with offices in State College, PA and Lewistown, PA, effective July 31, 2020.

Key Points: 
  • NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ --Radiation Business Solutions (RBS) announced that they have reached an agreement to purchase MBR Medical Billing, Inc., a radiation oncology medical billing company with offices in State College, PA and Lewistown, PA, effective July 31, 2020.
  • The MBR acquisition edges us closer to our national goal of 4,000 daily radiation oncology patients with reduced financial toxicity.
  • Radiation Business Solutions, headquartered in Joelton, Tennessee, provides billing, management, de novo center development, and joint venture opportunity to radiation oncologists in both freestanding and hospital centers.
  • With the addition of MBR, RBS now serves nearly 120 physicians at over 60 cancer centers located in 23 states.

Radiation Dose Management Market worth $422.65 million by 2025 - Exclusive Report by MarketsandMarkets™

Monday, August 3, 2020 - 1:30pm

The oncology segment accounted for the largest market share in 2019.

Key Points: 
  • The oncology segment accounted for the largest market share in 2019.
  • This has resulted in the rising adoption of imaging techniques for cancer detection and treatment planning, thus driving the demand for radiation dose management software as well.
  • Based on end users, the market is segmented into hospitals, ambulatory care settings, and other end users.
  • The major players in the Radiation Dose Management Market are Bayer AG (Germany), GE Healthcare (US), PACSHealth, LLC (US), and Sectra Medical Systems (Sweden).

Radiation Dose Management Market worth $422.65 million by 2025 - Exclusive Report by MarketsandMarkets™

Monday, August 3, 2020 - 1:30pm

The oncology segment accounted for the largest market share in 2019.

Key Points: 
  • The oncology segment accounted for the largest market share in 2019.
  • This has resulted in the rising adoption of imaging techniques for cancer detection and treatment planning, thus driving the demand for radiation dose management software as well.
  • Based on end users, the market is segmented into hospitals, ambulatory care settings, and other end users.
  • The major players in the Radiation Dose Management Market are Bayer AG (Germany), GE Healthcare (US), PACSHealth, LLC (US), and Sectra Medical Systems (Sweden).

Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

Monday, August 3, 2020 - 1:30pm

Co-60 irradiation is one of the quickest and most effective methods for sterilizing large volumes of this equipment.

Key Points: 
  • Co-60 irradiation is one of the quickest and most effective methods for sterilizing large volumes of this equipment.
  • Medical isotopes and nuclear medicine are proving to be effective in sterilizing, detecting, and fighting COVID-19 and guiding successful treatment.
  • In addition to damaging the patients lungs, this virus also attacks the heart, the blood vessels, liver, intestines, brain, and nervous system.
  • Unfortunately, as a result, many of our COVID-19 survivors will need serious medical help for months or years to come.

OrthoPediatrics Corp. Achieves 500th Case with FIREFLY® Pedicle Screw Navigation Guides

Monday, August 3, 2020 - 2:00pm

WARSAW, Ind., Aug. 03, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the 500th case performed with the FIREFLY Pedicle Screw Navigation Guides (FIREFLY) technology in collaboration with Mighty Oak Medical.

Key Points: 
  • WARSAW, Ind., Aug. 03, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (OrthoPediatrics or the Company) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the 500th case performed with the FIREFLY Pedicle Screw Navigation Guides (FIREFLY) technology in collaboration with Mighty Oak Medical.
  • The mechanical constraint provided by the 3D printed patient-specific guides also reduces intraoperative radiation and makes screw placement faster and more efficient.
  • This easy-to-use technology is a unique and cost-effective alternative to complex and expensive navigation systems.
  • David Bailey, President of OrthoPediatrics, added, We are extremely proud of our partnership with Mighty Oak Medical, and reaching this significant milestone with the FIREFLY technology.

Sirtex Medical Launches State-of-the-Art SIROS™ System for Advanced SIR-Spheres® Resin Microspheres Delivery

Monday, August 3, 2020 - 1:00pm

Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS , an innovative system for the delivery of SIR-Spheres Y-90 resin microspheres.

Key Points: 
  • Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS , an innovative system for the delivery of SIR-Spheres Y-90 resin microspheres.
  • With the systems visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres microspheres delivery.
  • Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.
  • Sirtexs current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres.